All In Biotech

Drug Trial Radar · NCT07351968

A Phase Ib Study to Evaluate the Efficacy and Safety of HRS-2129 in Patients With Knee Osteoarthritis

A Multicenter, Randomized, Double-blind, Agent-positive and Placebo-controlled, Parallel-group Phase Ib Study to Evaluate the Efficacy and Safety of HRS-2129 in Patients With Knee Osteoarthritis

Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 202 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

202

Actual

Start

Mar 10, 2026

Primary completion

Jul 17, 2026

Study completion Jul 17, 2026

Sponsor

Sponsor type
Industry
First posted
Jan 20, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: To explore the effectiveness of different doses of HRS-2129 in the treatment of patients with moderate to severe pain in knee osteoarthritis. Secondary Objectives: To evaluate the safety of different doses of HRS-2129 for the treatment of patients with moderate to severe pain in knee osteoarthritis; To evaluate the population pharmacokinetic profile of HRS-2129 in patients with knee osteoarthritis.

Conditions

  • Moderate Pain in Knee Osteoarthritis
  • Severe Pain in Knee Osteoarthritis

Interventions

  • HRS-2129 TabletDrug

    HRS-2129 tablet.

  • Celecoxib capsuleDrug

    Celecoxib capsule.

  • Celecoxib Capsule PlaceboDrug

    Celecoxib capsule placebo.

  • HRS-2129 Tablet PlaceboDrug

    HRS-2129 tablet placebo.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale scores.Time frame: At week 4.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Drum Tower Hospital affiliated to Nanjing University School of Medicine

    Nanjing, Jiangsu, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.